Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Epidemic Kaposi's sarcoma

M Cianfrocca¹, J H Roenn

¹Northwestern University Medical School, Division of Hematology/Oncology, Chicago, Illinois, USA.

Oncology (Williston Park, N.Y.)

|October 21, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Operable breast cancer.

Current treatment options in oncology·2002

Same author

Treatment of Kaposi's sarcoma.

Cancer treatment and research·2001

Same author

Wasting and cachexia in patients with HIV.

AIDS patient care and STDs·1997

Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026

Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026

Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026

Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026

Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026

Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026

See all related articles

Kaposi's sarcoma (KS), a common HIV-1 malignancy, often requires systemic therapy. Treatment options range from local therapies for early stages to chemotherapy for advanced disease, with new agents emerging.

Area of Science:

Oncology
Infectious Diseases
Dermatology

Background:

Kaposi's sarcoma (KS) is the most frequent malignancy in individuals with human immunodeficiency virus type 1 (HIV-1) infection.
KS can lead to substantial patient morbidity and typically follows a progressive clinical course.
While local therapies may palliate early-stage indolent KS, advanced or rapidly progressing disease necessitates systemic treatment.

Purpose of the Study:

To review the current treatment strategies for Kaposi's sarcoma (KS).
To discuss the role of various therapeutic agents in managing KS based on disease stage and patient immune status.
To highlight emerging therapeutic approaches for KS.

Main Methods:

Review of existing literature on Kaposi's sarcoma treatment.

Related Experiment Videos

Analysis of therapeutic options including local therapies, interferon-alfa, and chemotherapy.

Discussion of the role of antiretroviral agents in conjunction with KS treatment.

Main Results:

Early indolent KS may be managed with local therapies for palliation.
Interferon-alfa, with or without antiretroviral agents, is effective for patients with preserved immune function.
Chemotherapy is the preferred treatment for symptomatic visceral, pulmonary, or rapidly progressive cutaneous KS.
A growing number of treatment agents are available for KS management.

Conclusions:

Treatment selection for KS depends on disease stage, progression rate, and immune status.
Systemic therapies, including interferon-alfa and chemotherapy, are crucial for advanced KS.
Future treatments may involve pathogenesis-based therapies targeting the KS-associated herpesvirus (KSHV).